Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Biological/Research Material for H1N1 Influenza Virus Vaccine Research
Case ID:
TAB-2022
Web Published:
12/6/2022
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice.
The materials can be used for research purposes and in particular in the area of influenza virus vaccines.
The related publications listed below demonstrate the usefulness of this biological material in influenza virus vaccine research.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech?title=Biological%2fResearch_ Material_for_H1N1_Influenza_Virus_Vaccine_Research
Keywords:
A/PR/8/34
Attenuated
AXXXXX
DCXXXX
DDXXXX
DXXXXX
EXPRESSES
H1N1
Ha
Haemagglutinin
INFLUENZA
MVA
Np
NUCLEOPROTEIN
RESEARCH MATERIAL
That
vaccinia
virus
Bookmark this page
Download as PDF
For Information, Contact:
Benjamin Hurley
Office of Technology Transfer Center
NIH Technology Transfer
240-669-5092
benjamin.hurley@nih.gov